468 related articles for article (PubMed ID: 36902391)
21. Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice.
Liu X; Wang W; Chen HL; Zhang HY; Zhang NX
Acta Pharmacol Sin; 2019 Oct; 40(10):1259-1268. PubMed ID: 31089202
[TBL] [Abstract][Full Text] [Related]
22. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer's disease.
Zhang Z; Yi P; Yang J; Huang J; Xu P; Hu M; Zhang C; Wang B; Peng W
J Ethnopharmacol; 2020 Mar; 249():112371. PubMed ID: 31683034
[TBL] [Abstract][Full Text] [Related]
23. Improving mouse models for the study of Alzheimer's disease.
Reagan AM; Onos KD; Heuer SE; Sasner M; Howell GR
Curr Top Dev Biol; 2022; 148():79-113. PubMed ID: 35461569
[TBL] [Abstract][Full Text] [Related]
24. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
[TBL] [Abstract][Full Text] [Related]
25. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
26. Targeted metabolomics and medication classification data from participants in the ADNI1 cohort.
St John-Williams L; Blach C; Toledo JB; Rotroff DM; Kim S; Klavins K; Baillie R; Han X; Mahmoudiandehkordi S; Jack J; Massaro TJ; Lucas JE; Louie G; Motsinger-Reif AA; Risacher SL; ; ; Saykin AJ; Kastenmüller G; Arnold M; Koal T; Moseley MA; Mangravite LM; Peters MA; Tenenbaum JD; Thompson JW; Kaddurah-Daouk R
Sci Data; 2017 Oct; 4():170140. PubMed ID: 29039849
[TBL] [Abstract][Full Text] [Related]
27. Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives.
Lista S; González-Domínguez R; López-Ortiz S; González-Domínguez Á; Menéndez H; Martín-Hernández J; Lucia A; Emanuele E; Centonze D; Imbimbo BP; Triaca V; Lionetto L; Simmaco M; Cuperlovic-Culf M; Mill J; Li L; Mapstone M; Santos-Lozano A; Nisticò R
Ageing Res Rev; 2023 Aug; 89():101987. PubMed ID: 37343679
[TBL] [Abstract][Full Text] [Related]
28. Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer's disease using UPLC/ESI-Q-TOF mass spectrometry.
Chu H; Zhang A; Han Y; Lu S; Kong L; Han J; Liu Z; Sun H; Wang X
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():50-61. PubMed ID: 26896572
[TBL] [Abstract][Full Text] [Related]
29. Lipidomics of Alzheimer's disease.
Touboul D; Gaudin M
Bioanalysis; 2014 Feb; 6(4):541-61. PubMed ID: 24568356
[TBL] [Abstract][Full Text] [Related]
30. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease.
Xu XH; Huang Y; Wang G; Chen SD
Neurosci Bull; 2012 Oct; 28(5):641-8. PubMed ID: 23054640
[TBL] [Abstract][Full Text] [Related]
31. Serum Metabolomic and Lipidomic Profiling Reveals Novel Biomarkers of Efficacy for Benfotiamine in Alzheimer's Disease.
Bhawal R; Fu Q; Anderson ET; Gibson GE; Zhang S
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947984
[TBL] [Abstract][Full Text] [Related]
32. Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer's disease.
González-Domínguez R; García-Barrera T; Vitorica J; Gómez-Ariza JL
Electrophoresis; 2015 Feb; 36(4):577-87. PubMed ID: 25393935
[TBL] [Abstract][Full Text] [Related]
33. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study.
Mahajan UV; Varma VR; Griswold ME; Blackshear CT; An Y; Oommen AM; Varma S; Troncoso JC; Pletnikova O; O'Brien R; Hohman TJ; Legido-Quigley C; Thambisetty M
PLoS Med; 2020 Jan; 17(1):e1003012. PubMed ID: 31978055
[TBL] [Abstract][Full Text] [Related]
34. Metabolic profiling of the effects of ginsenoside Re in an Alzheimer's disease mouse model.
Li J; Liu Y; Li W; Wang Z; Guo P; Li L; Li N
Behav Brain Res; 2018 Jan; 337():160-172. PubMed ID: 28927718
[TBL] [Abstract][Full Text] [Related]
35. UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer's disease cell model induced by Aβ
Zhang M; Liu Y; Liu M; Liu B; Li N; Dong X; Hong Z; Chai Y
Metabolomics; 2019 Jan; 15(2):13. PubMed ID: 30830431
[TBL] [Abstract][Full Text] [Related]
36. Insulin resistance in Alzheimer's disease: The genetics and metabolomics links.
Amin AM; Mostafa H; Khojah HMJ
Clin Chim Acta; 2023 Jan; 539():215-236. PubMed ID: 36566957
[TBL] [Abstract][Full Text] [Related]
37. Targeted Metabolomic Analysis of the Eye Tissue of Triple Transgenic Alzheimer's Disease Mice at an Early Pathological Stage.
Shen L; Tang X; Zhang H; Zhuang H; Lin J; Zhao Y; Liu X
Mol Neurobiol; 2023 Dec; 60(12):7309-7328. PubMed ID: 37553545
[TBL] [Abstract][Full Text] [Related]
38. Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development.
Peña-Bautista C; Baquero M; Vento M; Cháfer-Pericás C
Curr Neuropharmacol; 2019; 17(7):630-647. PubMed ID: 30255758
[TBL] [Abstract][Full Text] [Related]
39. The role of genetic risk factors of Alzheimer's disease in synaptic dysfunction.
Fu WY; Ip NY
Semin Cell Dev Biol; 2023 Apr; 139():3-12. PubMed ID: 35918217
[TBL] [Abstract][Full Text] [Related]
40. Recent advances from metabolomics and lipidomics application in alzheimer's disease inspiring drug discovery.
Cuperlovic-Culf M; Badhwar A
Expert Opin Drug Discov; 2020 Mar; 15(3):319-331. PubMed ID: 31619081
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
